Estimating the Long Term Cost Savings from the Treatment of Alzheimer's Disease: A Modelling Approach

Author： Neumann P.J.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.17, Iss.1, 2000-01, pp. : 109-109

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Estimating Long Term Cost Savings from Treatment of Alzheimer's Disease: A Modelling Approach

By Fenn P.  

PharmacoEconomics, Vol. 16, Iss. 2, 1999-08 ,pp. : 165-174

Adis International

Access to resources Recommend Favorite

Potential Savings in the Cost of Caring for Alzheimer's Disease: Treatment with Rivastigmine

By Brett Hauber A.  

PharmacoEconomics, Vol. 17, Iss. 4, 2000-04 ,pp. : 351-360

Adis International

Access to resources Recommend Favorite

Potential Savings in the Cost of Caring for Alzheimer's Disease: Treatment with Rivastigmine

By Linkins K.W.  

PharmacoEconomics, Vol. 18, Iss. 6, 2000-12 ,pp. : 609-612

Adis International

Access to resources Recommend Favorite

Long-term cost savings with alteplase following stroke

By  

Inpharma, Vol. 1, Iss. 1575, 2007-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer’s Disease

By Wilcock G.  

Drugs & Aging, Vol. 20, Iss. 10, 2003-01 ,pp. : 777-789

Adis International

Access to resources Recommend Favorite